Potent and selective inhibition of SARS coronavirus replication by aurintricarboxylic acid

The severe acute respiratory syndrome virus (SARS) is a coronavirus that instigated regional epidemics in Canada and several Asian countries in 2003. The newly identified SARS coronavirus (SARS-CoV) can be transmitted among humans and cause severe or even fatal illnesses. As preventive vaccine devel...

Full description

Saved in:
Bibliographic Details
Published in:Biochemical and biophysical research communications 2004-08, Vol.320 (4), p.1199-1203
Main Authors: He, Runtao, Adonov, Anton, Traykova-Adonova, Maya, Cao, Jingxin, Cutts, Todd, Grudesky, Elsie, Deschambaul, Yvon, Berry, Jody, Drebot, Michael, Li, Xuguang
Format: Article
Language:English
Subjects:
Animals
Antiviral Agents - pharmacology
Antiviral Agents - therapeutic use
Aurintricarboxylic acid
Aurintricarboxylic Acid - pharmacology
Cell Division - drug effects
Chlorocebus aethiops
Coronavirus, SARS-CoV
Dose-Response Relationship, Drug
Inhibition
Reproducibility of Results
SARS
SARS coronavirus
SARS Virus - drug effects
SARS Virus - growth & development
SARS Virus - ultrastructure
Sensitivity and Specificity
Severe Acute Respiratory Syndrome - drug therapy
Severe Acute Respiratory Syndrome - virology
Vero Cells
Virus Replication - drug effects
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:The severe acute respiratory syndrome virus (SARS) is a coronavirus that instigated regional epidemics in Canada and several Asian countries in 2003. The newly identified SARS coronavirus (SARS-CoV) can be transmitted among humans and cause severe or even fatal illnesses. As preventive vaccine development takes years to complete and adverse reactions have been reported to some veterinary coronaviral vaccines, anti-viral compounds must be relentlessly pursued. In this study, we analyzed the effect of aurintricarboxylic acid (ATA) on SARS-CoV replication in cell culture, and found that ATA could drastically inhibit SARS-CoV replication, with viral production being 1000-fold less than that in the untreated control. Importantly, when compared with IFNs α and β, viral production was inhibited by more than 1000-fold as compared with the untreated control. In addition, when compared with IFNs α and β, ATA was approximately 10 times more potent than IFN α and 100 times more than interferon β at their highest concentrations reported in the literature previously. Our data indicated that ATA should be considered as a candidate anti-SARS compound for future clinical evaluation.
ISSN:0006-291X
1090-2104
DOI:10.1016/j.bbrc.2004.06.076